The agency in brief

ANRS | Emerging Infectious Diseases, an autonomous agency of Inserm, supports research to provide scientific responses to infectious diseases in times of crisis and over the long term.

Last updated on 20 November 2023

An extensive research field

Successor to the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) – founded to respond to the urgency and extent of the HIV/AIDS epidemic – and to the Inserm REACTing consortium, ANRS | Emerging Infectious Diseases was created on 1 January 2021.

We facilitate, coordinate, evaluate and fund research into HIV/AIDS, viral hepatitis, sexually transmitted infections, tuberculosis, and emerging and re-emerging infectious diseases such as COVID-19, viral haemorrhagic fevers and arboviruses.

We cover all areas of research: basic, translational, clinical, public health and the human and social sciences.


A unique governance model

Under the supervision of the French Ministries of Higher Education and Research and Health and Prevention, our agency federates an inter-institutional network of national and international doctors and researchers, patient associations and civil society representatives, with their full integration within our governance and operations. This co-construction dynamic guarantees that the projects we implement are in line with the expectations of the communities concerned, with the aim of limiting the health, economic and social impacts of epidemics.

An international reach

We are developing a global health approach according to One Health principles, which concern the links between human health, animal health and the environment, thereby reinforcing France’s response in the event of a crisis. Our agency is part of an international effort  particularly in close conjunction with Europe and with a network of partners in low- and middle-income countries to fight against combat epidemics.

Our desire is to make ANRS | Emerging Infectious Diseases an agency of researchers, for researchers, which removes obstacles to research into infectious pathogens, and facilitates, supports and assists it

Key figures (end 2022)

73 M
million euros total budget, 87% of which dedicated to funding research
research projects funded and/or sponsored (around 100 more than in 2021)
40 000+
patients participating in clinical research For more information

* Mandatory fields

Your personal details

Your request